The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future treatments.
Benjamin Bakall, MD, PhD
Advertisement
Director of Clinical Research at Associated Retina Consultants, and Clinical Assistant Professor at University of Arizona College of Medicine – Phoenix
Articles by Benjamin Bakall, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Treating myopia today: US-focused treatments, challenges, and global insights
2
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
3
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
4
FDA clears BVI’s FineVision HP trifocal IOL for the US market
5
.png "Optometry Times"){kind=logo}
